- Home
- BON vs TOVX Comparison
BON vs TOVX Comparison
Compare BON & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- TOVX
- Stock Information
- Founded
- BON 2006
- TOVX 2001
- Country
- BON China
- TOVX United States
- Employees
- BON N/A
- TOVX N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- TOVX Health Care
- Exchange
- BON Nasdaq
- TOVX Nasdaq
- Market Cap
- BON 4.3M
- TOVX 4.7M
- IPO Year
- BON 2021
- TOVX 2006
- Fundamental
- Price
- BON $0.06
- TOVX $1.16
- Analyst Decision
- BON
- TOVX Strong Buy
- Analyst Count
- BON 0
- TOVX 1
- Target Price
- BON N/A
- TOVX $6.00
- AVG Volume (30 Days)
- BON 34.9M
- TOVX 23.1K
- Earning Date
- BON 04-11-2025
- TOVX 05-06-2025
- Dividend Yield
- BON N/A
- TOVX N/A
- EPS Growth
- BON N/A
- TOVX N/A
- EPS
- BON 0.17
- TOVX N/A
- Revenue
- BON $23,844,556.00
- TOVX N/A
- Revenue This Year
- BON $223.38
- TOVX N/A
- Revenue Next Year
- BON $18.82
- TOVX N/A
- P/E Ratio
- BON $0.49
- TOVX N/A
- Revenue Growth
- BON N/A
- TOVX N/A
- 52 Week Low
- BON $0.07
- TOVX $1.03
- 52 Week High
- BON $5.31
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- BON 30.08
- TOVX 44.04
- Support Level
- BON $0.08
- TOVX $1.08
- Resistance Level
- BON $0.18
- TOVX $1.21
- Average True Range (ATR)
- BON 0.07
- TOVX 0.07
- MACD
- BON -0.01
- TOVX 0.00
- Stochastic Oscillator
- BON 0.11
- TOVX 55.56
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.